Jump to content

TheraP trial of Lutetium-177 open now in Melbourne


Recommended Posts

JimJimJimJim

Jim Marshall (not a doctor) said ...

The clinical trial testing Lutetium-177 therapy against the existing standard therapy (Cabazitaxel (Jevtana)) is taking its first men.

It starts at the Peter MacCallum Cancer Center in Melbourne (PeterMac), and other sites will be progressively added.

The Prostate Cancer Foundation of Australia (PCFA), with which we are affiliated, has co-sponsored the trial.

Below is the message that Daniel Moore of PCFA sent announcing the start.

... end Jim

In July 2017 PCFA and ANZUP launched the first Australian trial of a ground-breaking nuclear medicine treatment (Lutetium – 177 PSMA radionuclide therapy) for men with advanced prostate cancer, the TheraP Trial.

 

Today we are pleased to announce this trial is open at Peter MacCallum Cancer Centre in Melbourne with the additional sites to open in the following months.

 

This is an exciting trial and we are aware that you may have members of your group or the community ask you for further information. It is important to remember this treatment won’t be suitable for all those who have prostate cancer. 

 

As such, for further details and advice regarding eligibility, please ask anyone interested to print off the trial and contact details from the Australian and New Zealand Clinical Trials Registry (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=6899&isClinicalTrial=True) and speak with their treating physician.

 

To learn more, please view the information page via ANZUP here: http://www.anzup.org.au/content.aspx?page=lutetiumprostatecancertrial.

Link to post
Share on other sites
×
×
  • Create New...